Lincoln Pharmaceuticals Limited (NSE:LINCOLN)

Market Cap	11.99B +7.1%
Revenue (ttm)	6.71B +7.7%
Net Income	878.94M +6.7%
EPS	43.88 +6.7%
Shares Out	n/a
PE Ratio	13.64
Forward PE	n/a
Dividend	1.80 (0.30%)
Ex-Dividend Date	Sep 12, 2025

Volume	35,756
Open	598.75
Previous Close	598.50
Day's Range	574.00 - 598.80
52-Week Range	440.00 - 770.00
Beta	0.37
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Lincoln Pharmaceuticals

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East As...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1979
• Employees: 1,853
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: LINCOLN

Financial Performance

In fiscal year 2026, Lincoln Pharmaceuticals's revenue was 6.71 billion, an increase of 7.67% compared to the previous year's 6.23 billion. Earnings were 878.94 million, an increase of 6.74%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 22, 2026

Data Sources Report a data error